+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis A immunoglobulin Market - Global Forecast 2026-2032- Product Image
Hepatitis A immunoglobulin Market - Global Forecast 2026-2032- Product Image
Sale

Hepatitis A immunoglobulin Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6152618
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hepatitis A immunoglobulin Market is projected to reach USD 1.29 Billion in 2026. It is expected to continue growing at a CAGR of 10.41%, reaching USD 2.34 Billion by 2032.

Hepatitis A Immunoglobulin: Executive Overview

Hepatitis A immunoglobulin is used for short-term passive protection against hepatitis A virus infection, particularly after exposure or when vaccination is unsuitable or insufficiently timely. Demand is shaped by outbreak response, travel medicine, public-health protocols, immunocompromised-patient management, and access to plasma-derived medicinal products. Clinical practice increasingly distinguishes immunoglobulin’s role from active vaccination, with selection depending on exposure timing, age, immune status, comorbidities, and local guidance.

Public-Health Shifts Reshaping Hepatitis A Immunoglobulin Use

The landscape is being reshaped by stronger emphasis on prevention, outbreak preparedness, and targeted post-exposure intervention. Health systems are refining protocols for foodborne outbreaks, household and institutional exposure, travelers, and patients at elevated risk of severe disease. Plasma collection, donor screening, pathogen-reduction measures, cold-chain requirements, and regulatory controls remain central to reliable supply. Greater coordination between immunization programs, infectious-disease services, pharmacies, and emergency-response agencies is also influencing how products are accessed and administered.

How Artificial Intelligence Can Improve Hepatitis A Immunoglobulin Pathways

Artificial intelligence can support hepatitis A immunoglobulin services without replacing clinical judgment. Potential applications include identifying exposure clusters from surveillance data, prioritizing investigations, improving demand planning, detecting cold-chain anomalies, and supporting eligibility checks against current clinical guidance. Natural-language tools may help summarize case records and public-health alerts, while analytics can assist plasma-collection planning and inventory allocation. Implementation requires validated data, transparent decision rules, privacy safeguards, human oversight, and careful monitoring for bias or inappropriate recommendations.

Regional Insights Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally benefits from established immunization infrastructure, specialized infectious-disease services, and defined post-exposure protocols, although access can vary by payer and jurisdiction. Latin America faces uneven vaccine coverage, periodic outbreaks, and differences in diagnostic and supply-chain capacity, making local public-health coordination important. Europe has mature regulatory and surveillance systems, with the European Union supporting cross-border standards while national procurement and clinical pathways remain relevant. The Middle East combines advanced urban health systems with substantial travel, pilgrimage, and migrant-population considerations. Africa’s needs are influenced by sanitation gaps, outbreak-prone settings, limited specialist access, and the importance of resilient cold chains. Asia-Pacific presents wide variation, from highly organized systems in developed economies to significant unmet prevention and response needs in densely populated or geographically remote areas.

Group Insights: ASEAN, BRICS, European Union, G7, GCC, and NATO

ASEAN countries must balance dense travel and trade networks with varied immunization coverage, surveillance capacity, and regulatory environments. BRICS members span substantial differences in healthcare infrastructure, domestic plasma policy, and public-health priorities, making coordination and locally appropriate procurement important. The European Union benefits from shared regulatory principles and cross-border disease surveillance, while national health systems determine implementation. G7 members generally have strong clinical guidance and laboratory capacity but still require targeted access for travelers, exposed contacts, and vulnerable patients. GCC states must account for high mobility, expatriate populations, and mass gatherings, alongside comparatively developed clinical infrastructure. NATO members may view hepatitis A preparedness through both civilian public health and operational medical-readiness planning, particularly for deployed personnel and international movements.

Country Insights: Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the US

Australia and Japan have strong preventive-health systems and established travel-medicine pathways, while South Korea combines advanced healthcare capacity with structured infectious-disease surveillance. China and India require approaches that reflect large populations, regional variation, urban-rural differences, and diverse healthcare access. Brazil and Mexico must address periodic outbreaks, uneven sanitation conditions, and differences between metropolitan and remote services. Canada and the United States rely on mature public-health and clinical networks, with jurisdictional variation affecting procurement and administration. France, Germany, Italy, Spain, and the United Kingdom operate within advanced regulatory and surveillance environments, while national guidelines and health-service organization shape delivery. Russia’s geography and regional disparities make distribution, surveillance, and continuity of supply important considerations.

Actions for Leaders: Strengthen Preparedness, Evidence, and Responsible Access

Industry leaders should align immunoglobulin planning with vaccination and outbreak-response policies rather than treating the product as a standalone intervention. Priorities include strengthening plasma and manufacturing resilience, qualifying multiple logistics pathways, maintaining temperature-controlled distribution, and preparing contingency inventories for localized events. Organizations should generate real-world evidence on appropriate use, collaborate with public-health authorities, support clinician education, and improve access pathways for vulnerable populations. Digital and AI-enabled tools should be deployed incrementally with clinical validation, cybersecurity controls, auditability, and clear accountability. Responsible stewardship also requires distinguishing medically justified use from routine substitution for active immunization.

Research Methodology for the Hepatitis A Immunoglobulin Executive Summary

This summary uses a structured qualitative assessment of hepatitis A immunoglobulin’s clinical role, public-health applications, access conditions, regulatory considerations, supply-chain requirements, and technology opportunities. The framework compares regional, group, and country contexts using factors such as hepatitis A epidemiology, immunization infrastructure, travel and population mobility, outbreak-response capacity, healthcare access, plasma-product governance, and cold-chain reliability. Interpretations are limited to evidence-supported market dynamics and do not provide market estimates, forecasts, market shares, or company-level assessments. Country and group observations are presented as contextual comparisons rather than quantitative rankings.

Conclusion: Focus Hepatitis A Immunoglobulin Where Timely Protection Matters Most

Hepatitis A immunoglobulin remains an important targeted tool for short-term passive protection when exposure has occurred or active vaccination is not appropriate or cannot provide timely protection. Its role will depend on disciplined clinical selection, dependable plasma-derived-product supply, effective surveillance, and coordinated public-health response. Regional and country differences make adaptable access strategies essential. Leaders that combine prevention, preparedness, evidence generation, resilient logistics, and carefully governed digital capabilities will be better positioned to support safe and appropriate use.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of travel medicine clinics boosting demand for hepatitis A immunoglobulin in global tourist hotspots
5.2. Regulatory approval of new high-concentration hepatitis A immunoglobulin formulations improving passive immunity in pediatric patients
5.3. Strategic collaborations between biopharmaceutical companies and contract manufacturing organizations to scale up hepatitis A immunoglobulin production capacity
5.4. Rising incidence of hepatitis A outbreaks in developing regions driving increased government procurement of immunoglobulin
5.5. Integration of hepatitis A immunoglobulin prophylaxis into routine post-exposure protocols in childcare and school settings
5.6. Technological advancements in antibody purification techniques driving cost-effective hepatitis A immunoglobulin yields
5.7. Implementation of cold chain optimization strategies to enhance distribution efficiency of hepatitis A immunoglobulin in remote areas
5.8. Surge in corporate travel and business tourism accelerating prophylactic hepatitis A immunoglobulin uptake among frequent travellers
5.9. Adoption of evidence-based dosing guidelines by healthcare professionals for hepatitis A immunoglobulin use in immunocompromised patients
5.10. Growing investment in recombinant antibody platforms challenging plasma-derived hepatitis A immunoglobulin manufacturers' market share
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hepatitis A immunoglobulin Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Diagnostic Centers
8.5. Hospitals
9. Hepatitis A immunoglobulin Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Contract Pharmacy
9.2.2. In-House Pharmacy
9.3. Online Pharmacy
9.3.1. Direct-To-Consumer
9.3.2. Third-Party Marketplace
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Hepatitis A immunoglobulin Market, by Indication
10.1. Introduction
10.2. Postexposure Prophylaxis
10.3. Preexposure Prophylaxis
11. Hepatitis A immunoglobulin Market, by Product Type
11.1. Introduction
11.2. Equine
11.3. Human Plasma Derived
12. Hepatitis A immunoglobulin Market, by Form
12.1. Introduction
12.2. Liquid
12.3. Lyophilized
13. Americas Hepatitis A immunoglobulin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hepatitis A immunoglobulin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hepatitis A immunoglobulin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols S.A.
16.3.2. CSL Limited
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Biotest AG
16.3.6. Kedrion S.p.A.
16.3.7. LFB S.A.
16.3.8. Bio Products Laboratory Ltd
16.3.9. Serum Institute of India Pvt. Ltd.
16.3.10. GC Biopharma Co., Ltd.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. HEPATITIS A IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEPATITIS A IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEPATITIS A IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHAI
FIGURE 26. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHSTATISTICS
FIGURE 27. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHCONTACTS
FIGURE 28. HEPATITIS A IMMUNOGLOBULIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEPATITIS A IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CONTRACT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CONTRACT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY EQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HUMAN PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HUMAN PLASMA DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 108. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 109. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 114. CANADA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 115. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 130. MEXICO HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 197. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 212. GERMANY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 213. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 228. FRANCE HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 245. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 260. ITALY HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 261. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 270. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 271. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 276. SPAIN HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA HEPATITIS A IMMUNOGLOBULIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 316. SO

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bio Products Laboratory Ltd
  • Biotest AG
  • C. H. Boehringer Sohn AG & Co. KG
  • CSL Limited
  • Eli Lilly and Company
  • GC Biopharma Co., Ltd.
  • Genfit S.A.
  • Grifols S.A.
  • Kedrion S.p.A.
  • LFB S.A.
  • Moderna, Inc.
  • Octapharma AG
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Immunoglobulin Product Market - Global Forecast 2026-2032 - Product Image

Immunoglobulin Product Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Anti-D Immunoglobulin Market Report 2026 - Product Image

Anti-D Immunoglobulin Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Human Rabies Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Human Rabies Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Intravenous Immunoglobulin Market Report 2026 - Product Image

Intravenous Immunoglobulin Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.